The present study aimed to investigate the significance of anti-androgen withdrawal and/or subsequent alternative anti-androgen therapy in patients with advanced prostate cancer (PC) who relapsed after initial maximum androgen blockade (MAB). MOMOZONO, HIROYUKI MIYAKE, HIDEAKI TEI, HIROMOTO HARADA, KEN-ICHI FUJISAWA, MASATO In this double-blind study of 126 male subjects with acne, a topical solution of the antiandrogen inocoterone, compared with vehicle, produced a modest but statistically significant reduction in the number of inflammatory acne lesions.Ĭlinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade No serious adverse reactions were encountered. Global assessments and changes in comedo counts and sebum excretion rates were not significantly different between the groups. This difference achieved statistical significance by week 12 (24% reduction vs 10%) and week 16 (26% reduction vs 13%) and, with longitudinal analysis, throughout the course of the study. Inflammatory papules and pustules showed greater reduction in the inocoterone-treated subjects than in the subjects treated with vehicle.
Baseline and monthly examinations included acne lesion counts and general and endocrine laboratory tests.
To test its topical effect on acne, 126 male subjects with facial acne completed a 16-week, multi-center, double-blind study in which the twice-daily application of a 10% solution of inocoterone was compared with vehicle solution.
Inocoterone acetate (RU 882) is a nonsteroidal antiandrogen that binds to the androgen receptor and has antiandrogenic activity in animal models. Lookingbill, D P Abrams, B B Ellis, C N Jegasothy, B V Lucky, A W Ortiz-Ferrer, L C Savin, R C Shupack, J L Stiller, M J Zone, J Jīecause acne is androgen dependent, antiandrogen therapy might improve the condition. The effect of a topical antiandrogen: results of a multicenter clinical trial.
0 kommentar(er)
